

Press release 2015-02-26

WntResearch finalizing phase 1 study and initiating phase 1b study

WntResearch is finalizing the phase 1 study with Foxy-5 and initiating an exploratory phase 1b study to optimize the conditions for the forthcoming phase 2 study.

WntResearch AB announces that they have now initiated treatment of the last patient out of three at the next highest dose level (dose level 7) in their clinical phase 1 trial with FOXY-5 and no drug-related toxicities have been observed. The study will continue as planned to dose level 8.

However, as only a limited number of patients have received biologically meaningful Foxy-5 doses in this study, it is not possible to make any conclusions on potential activity. Therefore WntResearch has decided to perform a follow-up phase 1b study when the last patient has finalized the last dose level (dose level 8). The primary goal of this study will be to further explore and determine the optimal dose of Foxy-5 to be used and which biomarkers to be studied in the randomized phase 2 study. The trial will focus on potential biological effects of Foxy-5 treatment and will include extensive biomarker studies on tumor biopsies and blood samples in selected patients before and after treatment with Foxy-5.

“We have now reached dose levels of Foxy-5 in our phase 1 study that are biologically meaningful and we will shortly finalize this study as planned” **says Nils Brünner, CEO.** “I am pleased to report that we have not observed any side effects, which means that Foxy-5 is well tolerated by patients at the given doses. Since the number of patients treated with relevant doses so far is too low to be conclusive, we are now taking the next step by increasing the number of patients and increasing the doses of Foxy-5 with the purpose of finding the most optimal setting for our planned phase 2 randomized study” **Nils Brünner adds.**

For additional information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.